Legal & General Group
CLVS

Legal & General Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Legal & General Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-559
Closed -$1K – 3451
2022
Q3 		$1K Sell
559
-27,431
-98% -$42.8K ﹤0.01% 3453
2022
Q2 		$50K Sell
27,990
-36,734
-57% -$54.2K ﹤0.01% 3004
2022
Q1 		$131K Buy
64,724
+410
+0.6% +$805 ﹤0.01% 2803
2021
Q4 		$174K Buy
64,314
+4,126
+7% +$15.3K ﹤0.01% 2769
2021
Q3 		$268K Buy
60,188
+20,949
+53% +$101K ﹤0.01% 2595
2021
Q2 		$228K Buy
39,239
+24,518
+167% +$144K ﹤0.01% 2504
2021
Q1 		$103K Buy
14,721
+214
+1% +$1.44K ﹤0.01% 2613
2020
Q4 		$70K Hold
14,507
– – ﹤0.01% 2698
2020
Q3 		$85K Sell
14,507
-1,976
-12% -$11.8K ﹤0.01% 2534
2020
Q2 		$111K Buy
16,483
+6,576
+66% +$49.8K ﹤0.01% 2499
2020
Q1 		$63K Sell
9,907
-13,642
-58% -$109K ﹤0.01% 2531
2019
Q4 		$246K Buy
23,549
+125
+0.5% +$909 ﹤0.01% 2349
2019
Q3 		$92K Buy
23,424
+1,577
+7% +$12.8K ﹤0.01% 2550
2019
Q2 		$324K Buy
21,847
+1,192
+6% +$21.5K ﹤0.01% 2233
2019
Q1 		$513K Buy
20,655
+198
+1% +$4.96K ﹤0.01% 2150
2018
Q4 		$368K Buy
20,457
+4,711
+30% +$96.3K ﹤0.01% 2185
2018
Q3 		$463K Hold
15,746
– – ﹤0.01% 2158
2018
Q2 		$716K Sell
15,746
-451
-3% -$21.9K ﹤0.01% 2026
2018
Q1 		$855K Sell
16,197
-3,115
-16% -$182K ﹤0.01% 1951
2017
Q4 		$1.31M Buy
19,312
+1,350
+8% +$94.4K ﹤0.01% 1788
2017
Q3 		$1.48M Buy
17,962
+2,269
+14% +$180K ﹤0.01% 1718
2017
Q2 		$1.46M Buy
15,693
+3,090
+25% +$189K ﹤0.01% 1686
2017
Q1 		$798K Buy
12,603
+1,087
+9% +$66.1K ﹤0.01% 1879
2016
Q4 		$510K Buy
11,516
+3,285
+40% +$116K ﹤0.01% 1976
2016
Q3 		$288K Sell
8,231
-252
-3% -$5.41K ﹤0.01% 1935
2016
Q2 		$118K Hold
8,483
– – ﹤0.01% 2008
2016
Q1 		$164K Buy
8,483
+3,072
+57% +$65K ﹤0.01% 1799
2015
Q4 		$186K Buy
5,411
+256
+5% +$16.5K ﹤0.01% 1774
2015
Q3 		$477K Buy
5,155
+545
+12% +$47.2K ﹤0.01% 1311
2015
Q2 		$397K Hold
4,610
– – ﹤0.01% 1396
2015
Q1 		$347K Buy
4,610
+923
+25% +$65.2K ﹤0.01% 1412
2014
Q4 		$209K Sell
3,687
-87
-2% -$4.57K ﹤0.01% 1548
2014
Q3 		$178K Buy
+3,774
New +$158K ﹤0.01% 1570

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Legal & General Group's CLVS Position: Q4 2022 in Review

Legal & General Group sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 559 shares — an estimated $1K sold.

Legal & General Group first reported a position in CLVS in Q3 2014 and held it in 33 quarters. The position peaked at $1.48M in Q3 2017. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Legal & General Group reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Legal & General Group sold 559 Clovis Oncology, Inc. shares in Q4 2022, an estimated $1K.
  • Legal & General Group first reported a position in Clovis Oncology, Inc. in Q3 2014 and held it in 33 quarters.
  • Legal & General Group's Clovis Oncology, Inc. position peaked at $1.48M in Q3 2017.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Legal & General Group's 13F filing for Q4 2022, filed 14 Feb 2023.